US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a clinical trial collaboration immuno-oncology firm Gritstone Oncology to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001.
This comprises sequential delivery of neoantigens to patients within an adenovirus-based vector (prime) and a self-replicating RNA-based vector (boost), in combination with B-MS’
programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab), and Opdivo plus Yervoy (ipilimumab), in patients with advanced solid tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze